Abstract: High-dose therapy (HDT) combined with autologous hematopoietic stem cell transplantation (AHSCT) is a standard treatment for relapsed or refractory aggressive lymphoma. However, the role of HDT/AHSCT in the first-line treatment of lymphoma remains controversial, and related issues about its application in different subtypes of lymphoma should be addressed. This article brief -ly reviewed the clinical progress in AHSCT for malignant lymphoma treatment.